coronavirus
singl
strand
posit
sens
rna
virus
contain
largest
nonseg
rna
viru
genom
coronavirus
respons
highli
preval
diseas
human
anim
divid
group
alpha
beta
gamma
base
antigen
genet
criteria
alpha
beta
coronavirus
infect
mammal
home
sever
acut
respiratori
syndrom
coronaviru
sarscov
classifi
beta
group
coronavirus
felin
coronavirus
belong
alpha
coronavirus
affect
anim
famili
felida
includ
cheetah
wildcat
lion
leopard
heeney
et
al
kennedi
et
al
felin
coronaviru
classifi
serotyp
ii
felin
serotyp
canin
coronavirus
consid
origin
common
ancestor
felin
coronaviru
serotyp
ii
appear
deriv
recombin
canin
coronaviru
felin
coronaviru
serotyp
spike
protein
herrewegh
et
al
motokawa
et
al
felin
coronaviru
serotyp
preval
serotyp
ii
felin
coronavirus
serotyp
caus
mild
asymptomat
enter
felin
infecti
periton
fip
cat
benetka
et
al
kummrow
et
al
pedersen
et
al
fip
fatal
diseas
cat
current
one
lead
infecti
caus
fatal
among
young
cat
multipl
cat
household
shelter
pedersen
felin
enter
coronaviru
fecv
caus
asymptomat
mild
enter
among
cat
high
preval
pedersen
et
al
vogel
et
al
unlik
fecv
confin
intestin
epithelium
fip
viru
fipv
gain
abil
replic
macrophag
monocyt
mutat
endogen
fecv
spread
entir
bodi
progress
fip
also
influenc
host
immun
respons
weak
defect
cellmedi
immun
respons
associ
develop
fip
pedersen
despit
fatal
natur
increas
incid
fip
effect
prophylact
therapeut
agent
current
avail
fipv
coronavirus
clubshap
protein
envelop
bind
cell
undergo
membran
fusion
gain
entri
cytoplasm
cleavag
protein
vari
among
coronavirus
coronavirus
includ
sarscov
murin
hepat
viru
mhv
protein
cleav
cellular
cathepsin
cystein
proteas
typic
present
within
endosomelysosom
cell
cytoplasm
qiu
et
al
simmon
et
al
fip
fecv
also
found
highli
depend
presenc
cathepsin
b
cleavag
protein
enabl
cell
entri
viru
replic
regan
et
al
import
presenc
cathepsin
function
replic
felin
coronavirus
demonstr
inhibit
serotyp
ii
felin
coronavirus
includ
strain
cathepsin
b
inhibitor
irrevers
nonspecif
cystein
inhibitor
inhibit
cleavag
protein
regan
et
al
result
indic
cathepsin
b
may
serv
potenti
target
develop
therapeut
drug
felin
coronavirus
follow
entri
cell
coronavirus
express
polyprotein
cleav
viral
proteas
intermedi
matur
nonstructur
protein
viral
proteas
involv
cleavag
polyprotein
papainlik
proteas
proteas
papainlik
proteas
cleav
nproxim
region
proteas
cleav
viral
polyprotein
conserv
interdomain
junction
ziebuhr
et
al
coronaviru
proteas
like
mani
viral
proteas
human
immunodefici
hepat
c
viru
commerci
proteas
inhibitor
avail
highli
effect
regul
viru
replic
coronaviru
proteas
cystein
proteas
share
common
characterist
structur
function
properti
proteas
norovirus
picornavirus
respect
possess
chymotrypsinlik
fold
cystein
residu
nucleophil
conserv
activ
site
viral
proteas
play
essenti
role
viral
replic
consequ
attract
target
develop
antivir
drug
previous
report
gener
new
peptidyl
inhibitor
noroviru
proteas
broad
spectrum
activ
virus
possess
proteas
includ
felin
coronaviru
tiew
et
al
studi
studi
revers
mode
inhibit
proteas
inhibitor
compar
antivir
effect
proteas
inhibitor
cathepsin
inhibitor
replic
felin
coronavirus
cell
also
studi
combin
antivir
effect
cathepsin
b
inhibitor
felin
coronaviru
cell
cultur
summari
demonstr
peptidyl
transit
state
inhibitor
use
studi
revers
competit
inhibitor
proteas
potent
inhibit
replic
felin
coronavirus
cell
cultur
ec
effect
concentr
inhibit
viral
replic
nanomolar
rang
furthermor
combin
treatment
cell
exhibit
strong
synergist
activ
felin
coronaviru
result
indic
proteas
inhibitor
potenti
develop
antivir
drug
felin
coronavirus
singl
agent
combin
entri
blocker
compound
synthes
previous
describ
tiew
et
al
proteas
highli
conserv
among
coronavirus
felin
coronaviru
proteas
close
relat
tgev
proteas
therefor
clone
express
tgev
proteas
fluoresc
reson
energi
transfer
fret
assay
cdna
encod
full
length
proteas
tgev
miller
strain
amplifi
rtpcr
previous
describ
anand
et
al
primer
contain
nucleotid
sequenc
proteas
clone
well
nucleotid
histidin
forward
primer
forward
revers
primer
tctagaaaggagatataccatgcatcatcatcatcatcattcaggtttacggaaaatggc
tgevproxhor
ctcgagtcactgaagatttacaccatac
amplifi
product
subclon
vector
genscript
piscataway
nj
express
purif
proteas
perform
standard
method
describ
previous
lab
chang
et
al
takahashi
et
al
tiew
et
al
proteas
inhibitor
commerci
cathepsin
inhibitor
prepar
dmso
stock
solut
mm
dilut
assay
buffer
consist
hepe
mm
edta
glycerol
mm
nacl
mm
dtt
ph
tgev
proteas
final
concentr
substrat
edansvalasnserthrleuglnserglyleuargli
dabcyl
met
kuo
et
al
use
studi
compound
variou
concentr
preincub
tgev
proteas
min
volum
substrat
ad
mixtur
compound
ad
proteas
immedi
substrat
ad
enzymeinhibitor
mixtur
black
plate
mixtur
incub
min
fluoresc
read
obtain
micropl
reader
nm
excit
nm
emiss
wavelength
rel
fluoresc
unit
rfu
calcul
subtract
background
substrat
control
well
without
proteas
fluoresc
read
dosedepend
fret
inhibit
curv
fit
variabl
slope
four
paramet
use
graphpad
prism
softwar
la
jolla
ca
order
determin
compound
concentr
give
halfmaximum
respons
ic
separ
experi
tgev
proteas
incub
serial
dilut
assay
buffer
incub
min
follow
addit
variou
concentr
substrat
mixtur
incub
fluoresc
read
obtain
micropl
reader
everi
min
min
correct
factor
compens
inner
filter
effect
determin
empir
describ
previous
chang
et
al
cuerrier
et
al
jaulent
et
al
kinet
constant
k
determin
fit
initi
rate
michaelismenten
equat
use
graphpad
prism
softwar
lineweaverburk
plot
construct
use
graphpad
prism
softwar
determin
k
valu
well
type
enzym
inhibit
lastli
recoveri
enzymat
activ
tgev
proteas
time
rapid
dilut
experi
studi
demonstr
revers
bind
tgev
proteas
copeland
xie
et
al
rapid
dilut
experi
perform
incub
tgev
proteas
time
concentr
normal
use
reaction
dmso
concentr
approxim
time
greater
ic
valu
min
incub
mixtur
dilut
reaction
buffer
normal
reaction
condit
substrat
ad
fluoresc
read
obtain
micropl
reader
time
progress
curv
gener
crandel
ree
felin
kidney
crfk
cell
maintain
minim
essenti
medium
contain
fetal
bovin
serum
antibiot
wsu
strain
purchas
atcc
manassa
va
viru
infect
perform
follow
solvent
dmso
ad
variou
concentr
twoday
old
monolay
crfk
cell
prepar
well
plate
cell
incub
presenc
compound
solvent
h
compound
ad
time
viru
inocul
inocul
cell
multipl
infect
moi
moi
western
blot
analysi
viru
infect
cell
incub
presenc
compound
day
ec
determin
tcid
method
reed
muench
cell
lysat
crfk
cell
prepar
ad
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
sampl
buffer
contain
sonic
sec
protein
resolv
novex
bisglycin
gel
invitrogen
carlsbad
ca
transfer
nitrocellulos
membran
transfer
nitrocellulos
membran
incub
primari
antibodi
coronaviru
nucleocapsid
protein
biocompar
windham
nh
load
control
overnight
secondari
antibodi
conjug
peroxidas
h
follow
incub
chemiluminesc
substrat
supersign
west
pico
chemiluminesc
substrat
pierc
biotechnolog
rockford
il
signal
detect
xray
film
standard
tcid
method
dilut
sampl
use
viru
titrat
reed
muench
determin
toxic
concentr
cell
death
tc
crfk
cell
incub
combin
h
prior
inocul
moi
h
incub
viru
replic
assess
viru
titrat
use
tcid
method
drugdrug
interact
analyz
threedimension
model
prichard
shipman
prichard
shipman
use
macsynergi
ii
softwar
confid
limit
theoret
addit
interact
calcul
doserespons
curv
compound
individu
calcul
addit
surfac
subtract
experiment
determin
doserespons
surfac
give
region
synergist
antagonist
interact
result
surfac
appear
horizont
plane
synergi
interact
two
compound
addit
peak
plane
indic
synergi
antagon
respect
proteas
inhibit
assay
perform
use
floresc
substrat
deriv
cleavag
site
sarscov
examin
inhibit
proteas
inhibitori
effect
compound
final
concentr
activ
tgev
proteas
shown
cathepsin
b
inhibitor
pancystein
cathepsin
inhibitor
includ
control
remark
inhibit
activ
tgev
proteas
cathepsin
inhibitor
dosedepend
inhibit
tgev
proteas
activ
without
preincub
compound
proteas
shown
open
circl
fill
squar
respect
shown
enzymat
activ
proteas
incub
x
ic
concentr
recov
dilut
proteaseinhibitor
mixtur
final
concentr
dilut
inhibitor
concentr
ic
recoveri
enzymat
activ
time
indic
compound
revers
inhibitor
antivir
effect
proteas
inhibitor
cathepsin
inhibitor
studi
cell
cultur
replic
markedli
inhibit
presenc
tabl
howev
suppress
viru
replic
proteas
inhibitor
potent
h
indic
ec
valu
tabl
notabl
antivir
activ
decreas
substanti
time
tabl
proteas
inhibitor
ad
cell
time
viru
infect
ec
valu
compound
increas
compar
obtain
preincub
cell
compound
tabl
antivir
effect
proteas
inhibitor
select
activ
unrel
virus
influenza
viru
porcin
respiratori
reproduct
syndrom
viru
data
shown
antivir
activ
due
nonspecif
cytotox
sinc
proteas
inhibitor
show
cytotox
variou
cell
even
cathepsin
inhibitor
also
show
toxic
vitro
therapeut
indic
calcul
ratio
ec
tc
cathepsin
proteas
inhibitor
least
respect
h
post
viru
infect
result
demonstr
replic
felin
coronavirus
effect
inhibit
proteas
inhibitor
excel
safeti
margin
cell
combin
treatment
perform
investig
interact
two
compound
differ
mode
inhibit
replic
effect
combin
determin
strongli
synergist
analyz
mathemat
model
base
macsynergi
antivir
synergi
observ
averag
synergi
volum
confid
interv
two
experi
fig
b
tabl
absolut
valu
indic
signific
valu
synergi
exampl
virusinfect
crfk
cell
treat
result
log
reduct
viru
titer
contrast
combin
two
led
log
viral
titer
reduct
much
effect
either
compound
alon
indic
synergi
tabl
felin
infecti
periton
believ
caus
infecti
periton
viru
aris
chang
tissu
tropism
intestin
cell
macrophag
mutat
felin
enter
coronaviru
individu
cat
chang
et
al
vennema
et
al
underli
mechan
allow
tissu
tropism
chang
report
associ
mutat
open
read
frame
gene
aberr
immun
respons
host
detail
mechan
alter
tropism
clearli
establish
chang
et
al
chang
et
al
pedersen
et
al
poland
et
al
vennema
et
al
includ
use
immunosuppress
glucocorticoid
antibiot
hartmann
ritz
agent
use
includ
interferon
tumor
necrosi
inhibitor
propentofyllin
polyprenyl
immunostimul
ishida
et
al
legendr
bartg
ritz
et
al
howev
therapeut
efficaci
immun
modul
agent
shown
ineffect
need
investig
control
trial
fischer
et
al
ritz
et
al
ribavirin
report
reduc
replic
fipv
ic
tc
later
studi
use
specif
pathogen
free
cat
infect
fipv
show
ribavirin
treatment
mgkg
effect
reduc
fatal
sever
symptom
weiss
et
al
addit
studi
antivir
agent
directli
indirectli
target
viru
compon
andor
replic
step
limit
barlough
shacklett
hsieh
et
al
group
previous
report
seri
new
proteas
inhibitor
target
proteas
noroviru
tiew
et
al
coronaviru
proteas
classifi
chymotrypsinlik
cystein
proteas
share
remark
degre
conserv
activ
site
noroviru
proteas
dipeptidyl
proteas
inhibitor
incorpor
structur
glutamin
surrog
leucin
residu
correspond
site
substrat
tiew
et
al
amino
acid
residu
substrat
design
etc
start
scissil
bond
count
toward
nterminu
likewis
amino
acid
residu
resid
cterminu
side
scissil
bond
design
etc
schechter
berger
proteas
inhibitor
origin
develop
group
reflect
substrat
specif
noroviru
proteas
frequent
found
residu
posit
cleavag
site
glutamin
leucin
respect
amino
acid
residu
site
also
conserv
among
coronavirus
includ
tgev
fecv
fipv
mhv
human
coronavirus
yang
et
al
highli
conserv
featur
among
virus
encod
proteas
led
find
dipeptidyl
compound
potent
inhibit
replic
norovirus
picornavirus
coronavirus
includ
felin
coronavirus
cell
peptidyl
compound
previous
demonstr
target
coronaviru
proteas
fret
proteas
assay
crystal
structur
tgev
complex
possess
aldehyd
potent
electrophil
react
cystein
nucleophil
sulfur
activ
site
viru
proteas
revers
manner
bisulfit
adduct
warhead
synthes
precursor
aldehyd
sinc
bisulfit
adduct
convert
aldehyd
form
form
coval
bond
cystein
activ
site
viru
proteas
base
preliminari
result
rat
crystal
structur
complex
tgev
proteas
like
behav
prodrug
aldehyd
counterpart
studi
compar
antivir
activ
dipeptidyl
compound
cathepsin
b
inhibitor
nonspecif
cystein
cathepsin
inhibitor
felin
coronavirus
viru
strain
cell
cultur
adapt
type
ii
felin
coronavirus
confirm
caus
fip
experiment
set
pedersen
et
al
origin
thought
felin
enter
coronaviru
sinc
induc
inappar
mild
enter
without
caus
system
infect
experiment
infect
cat
pedersen
et
al
howev
subsequ
sequenc
analysi
studi
mutat
gene
may
contribut
develop
fipv
fecv
suggest
may
lost
virul
fipv
revert
fecv
biotyp
chang
et
al
herrewegh
et
al
pedersen
pedersen
et
al
studi
cathepsin
inhibitor
significantli
inhibit
replic
felin
coronavirus
h
although
potenc
lower
proteas
inhibitor
howev
rapid
loss
activ
observ
time
cell
cultur
without
daili
addit
compound
compar
proteas
inhibitor
shorter
durat
activ
cathepsin
inhibitor
viral
replic
specul
virus
overcom
antivir
blockad
impos
inhibit
cathepsin
activ
resynthesi
uninhibit
cathepsin
rel
instabl
cathepsin
inhibitor
media
antivir
effect
nonspecif
cathepsin
inhibit
felin
coronavirus
potent
inhibit
cathepsin
b
h
post
infect
may
explain
differ
affin
proteas
stabil
compound
potenti
presenc
cathepsin
cathepsin
b
abl
process
viral
polyprotein
report
previous
fipv
fecv
differ
requir
cathepsin
cleavag
protein
gain
entri
cell
cathepsin
b
l
requir
fecv
cathepsin
l
dispens
fipv
strain
cell
regan
et
al
suggest
differ
requir
cathepsin
among
viru
strain
proteas
inhibitor
ad
cell
time
viru
infect
antivir
activ
compound
reduc
compar
h
preincub
cell
inhibitor
reflect
increas
ec
valu
fret
assay
ic
valu
proteas
also
increas
howev
antivir
activ
cell
still
potent
nanomolar
ec
valu
even
inhibitor
ad
cell
time
viru
inocul
xray
crystallograph
studi
previous
show
bind
activ
site
form
revers
coval
bond
cystein
residu
activ
site
proteas
norwalk
viru
polioviru
tgev
studi
kinet
analysi
tgev
proteas
reveal
revers
competit
natur
inhibitor
examin
proteas
inhibitor
serotyp
felin
coronavirus
antivir
activ
studi
howev
expect
proteas
inhibitor
effect
serotyp
felin
coronavirus
sinc
proteas
conserv
among
coronavirus
proteas
inhibitor
also
inhibit
replic
tgev
mhv
previou
studi
sinc
proteas
inhibitor
act
differ
target
subsequ
investig
effect
combin
treatment
felin
coronaviru
cell
analysi
drugdrug
combin
confid
interv
macsynergi
softwar
show
synergi
volum
small
volum
antagon
observ
high
concentr
ad
cell
contain
tabl
high
concentr
synerg
activ
reduc
antivir
respons
singl
treatment
reach
high
synergi
evid
mid
rang
compound
concentr
use
found
signific
synergi
drug
cytotox
effect
concentr
use
result
show
entri
blocker
proteas
inhibitor
work
differ
stage
viru
life
cycl
act
synergist
concentr
shown
favor
drugdrug
interact
observ
felin
coronaviru
suggest
potenti
use
combin
compound
target
host
factor
involv
viru
entri
viru
proteas
felin
coronaviru
infect
summari
proteas
inhibitor
use
studi
found
highli
effect
felin
coronavirus
cell
antivir
effect
proteas
inhibitor
profound
inhibit
cathepsin
strong
synerg
effect
observ
combin
treatment
cathepsin
b
inhibitor
proteas
inhibitor
find
underscor
effect
proteas
inhibitor
felin
coronaviru
infect
potenti
use
proteas
inhibitor
singl
therapeut
agent
combin
cathepsin
b
inhibitor
